Protection of mitochondria prevents high-fat diet–induced glomerulopathy and proximal tubular injury

Kidney International

Volumn 90, Issue 5, 2016, Pages 997-1011

  Szeto, Hazel H ^a   Liu, Shaoyi ^a   Soong, Yi ^a   Alam, Nazia ^a,b   Prusky, Glen T ^a,b   Seshan, Surya V ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BURKE MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

endothelium; fibrosis; inflammation; mitochondria; obesity; podocyte

Indexed keywords

ADENYLATE KINASE; ELAMIPRETIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; ARGINYL-2,'6'-DIMETHYLTYROSYL-LYSYL-PHENYLALANINAMIDE; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL EXPANSION; CELL INFILTRATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS; KIDNEY CELL; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; KIDNEY TUBULE DAMAGE; LIPID DIET; LIPOTOXICITY; MACROPHAGE; MESANGIUM CELL; MITOCHONDRION; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTECTION; ANIMAL; APOPTOSIS; BODY WEIGHT; C57BL MOUSE; CAPILLARY; COMPLICATION; DRUG EFFECTS; ENDOPLASMIC RETICULUM STRESS; GLOMERULONEPHRITIS; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; METABOLISM; OBESITY; PRECLINICAL STUDY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; VASCULAR ENDOTHELIUM;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CAPILLARIES; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIUM, VASCULAR; GLOMERULONEPHRITIS; KIDNEY TUBULES, PROXIMAL; LIPID METABOLISM; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; OBESITY; OLIGOPEPTIDES; PODOCYTES;

EID: 84994165720     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.06.013     Document Type: Article

References (53)

1. 1 Wang, Y., Chen, X., Song, Y., et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 73 (2008), 19–33.
2. 2 Chertow, G.M., Hsu, C.Y., Johansen, K.L., The enlarging body of evidence: obesity and chronic kidney disease. J Am Soc Nephrol 17 (2006), 1501–1502.
3. 3 de Vries, A.P., Ruggenenti, P., Ruan, X.Z., et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol 2 (2014), 417–426.
4. 4 Chen, H.M., Liu, Z.H., Zeng, C.H., et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 48 (2006), 772–779.
5. 5 Deji, N., Kume, S., Araki, S., et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol 296 (2009), F118–F126.
6. 6 Shevalye, H., Lupachyk, S., Watcho, P., et al. Prediabetic nephropathy as an early consequence of the high-calorie/high-fat diet: relation to oxidative stress. Endocrinology 153 (2012), 1152–1161.
7. 7 Sun, Y.B., Qu, X., Howard, V., et al. Smad3 deficiency protects mice from obesity-induced podocyte injury that precedes insulin resistance. Kidney Int 88 (2015), 286–298.
8. 8 Ruggiero, C., Ehrenshaft, M., Cleland, E., et al. High-fat diet induces an initial adaptation of mitochondrial bioenergetics in the kidney despite evident oxidative stress and mitochondrial ROS production. Am J Physiol Endocrinol Metab 300 (2011), E1047–E1058.
9. 9 Wicks, S.E., Nguyen, T.T., Breaux, C., et al. Diet-induced obesity and kidney disease - in search of a susceptible mouse model. Biochimie 124 (2016), 65–73.
10. 10 Herman-Edelstein, M., Scherzer, P., Tobar, A., et al. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res 55 (2014), 561–572.
11. 11 Martinez-Garcia, C., Izquierdo-Lahuerta, A., Vivas, Y., et al. Renal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton organization in podocytes. PLoS One, 10, 2015, e0142291.
12. 12 van der Heijden, R.A., Bijzet, J., Meijers, W.C., et al. Obesity-induced chronic inflammation in high fat diet challenged C57BL/6J mice is associated with acceleration of age-dependent renal amyloidosis. Sci Rep, 5, 2015, 16474.
13. 13 Kume, S., Uzu, T., Araki, S., et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 18 (2007), 2715–2723.
14. 14 Lindholm, C.R., Ertel, R.L., Bauwens, J.D., et al. A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats. J Physiol Biochem 69 (2013), 165–175.
15. 15 Decleves, A.E., Mathew, A.V., Cunard, R., et al. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol 22 (2011), 1846–1855.
16. 16 Decleves, A.E., Zolkipli, Z., Satriano, J., et al. Regulation of lipid accumulation by AMP-activated kinase in high fat diet-induced kidney injury. Kidney Int 85 (2014), 611–623.
17. 17 Stacchiotti, A., Favero, G., Giugno, L., et al. Mitochondrial and metabolic dysfunction in renal convoluted tubules of obese mice: protective role of melatonin. PLoS One, 9, 2014, e111141.
18. 18 Munusamy, S., do Carmo, J.M., Hosler, J.P., et al. Obesity-induced changes in kidney mitochondria and endoplasmic reticulum in the presence or absence of leptin. Am J Physiol Renal Physiol 309 (2015), F731–F743.
19. 19 Coughlan, M.T., Nguyen, T.V., Penfold, S.A., et al. Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clin Sci (Lond) 130 (2016), 711–720.
20. 20 Birk, A.V., Liu, S., Soong, Y., et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 24 (2013), 1250–1261.
21. 21 Birk, A.V., Chao, W.M., Bracken, C., et al. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol 171 (2014), 2017–2028.
22. 22 Szeto, H.H., Birk, A.V., Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther 96 (2014), 672–683.
23. 23 Kang, L., Dai, C., Lustig, M.E., et al. Heterozygous SOD2 deletion impairs glucose-stimulated insulin secretion, but not insulin action, in high-fat-fed mice. Diabetes 63 (2014), 3699–3710.
24. 24 Thakur, V., Morse, S., Reisin, E., Functional and structural renal changes in the early stages of obesity. Contrib Nephrol 151 (2006), 135–150.
25. 25 Pusztaszeri, M.P., Seelentag, W., Bosman, F.T., Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 54 (2006), 385–395.
26. 26 Schrijvers, B.F., Flyvbjerg, A., De Vriese, A.S., The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65 (2004), 2003–2017.
27. 27 Pichaiwong, W., Hudkins, K.L., Wietecha, T., et al. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol 24 (2013), 1088–1102.
28. 28 Reidy, K., Kang, H.M., Hostetter, T., et al. Molecular mechanisms of diabetic kidney disease. J Clin Invest 124 (2014), 2333–2340.
29. 29 Mount, P., Davies, M., Choy, S.W., et al. Obesity-related chronic kidney disease-the role of lipid metabolism. Metabolites 5 (2015), 720–732.
30. 30 Dong, H., Czaja, M.J., Regulation of lipid droplets by autophagy. Trends Endocrinol Metab 22 (2011), 234–240.
31. 31 Long, Y.C., Zierath, J.R., AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116 (2006), 1776–1783.
32. 32 Reznick, R.M., Shulman, G.I., The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol 574 (2006), 33–39.
33. 33 Nakayama, T., Sato, W., Yoshimura, A., et al. Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney. Am J Pathol 176 (2010), 2198–2208.
34. 34 Abe, Y., Sakairi, T., Kajiyama, H., et al. Bioenergetic characterization of mouse podocytes. Am J Physiol Cell Physiol 299 (2010), C464–C476.
35. 35 Boini, K.M., Xia, M., Abais, J.M., et al. Activation of inflammasomes in podocyte injury of mice on the high fat diet: effects of ASC gene deletion and silencing. Biochim Biophys Acta 1843 (2014), 836–845.
36. 36 Zhao, K., Zhao, G.M., Wu, D., et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 279 (2004), 34682–34690.
37. 37 Birk, A.V., Chao, W.M., Liu, S., et al. Disruption of cytochrome c heme coordination is responsible for mitochondrial injury during ischemia. Biochim Biophys Acta 1847 (2015), 1075–1084.
38. 38 Sharma, K., Karl, B., Mathew, A.V., et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 4 (2013), 1901–1912.
39. 39 Wojtczak, L., Schonfeld, P., Effect of fatty acids on energy coupling processes in mitochondria. Biochim Biophys Acta 183 (1993), 41–57.
40. 40 Singh, R., Kaushik, S., Wang, Y., et al. Autophagy regulates lipid metabolism. Nature 458 (2009), 1131–1135.
41. 41 Singh, R., Cuervo, A.M., Autophagy in the cellular energetic balance. Cell Metab 13 (2011), 495–504.
42. 42 Steinberg, G.R., Michell, B.J., van Denderen, B.J., et al. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 4 (2006), 465–474.
43. 43 Awad, A.S., You, H., Gao, T., et al. Macrophage-derived tumor necrosis factor-alpha mediates diabetic renal injury. Kidney Int 88 (2015), 722–733.
44. 44 Tang, J., Yan, H., Zhuang, S., Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol, 2012, 2012, 608397.
45. 45 Szeto, H.H., Liu, S., Soong, Y., et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol 22 (2011), 1041–1052.
46. 46 Mizuguchi, Y., Chen, J., Seshan, S.V., et al. A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am J Physiol Renal Physiol 295 (2008), F1545–F1553.
47. 47 Hou, Y., Li, S., Wu, M., et al. Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy. Am J Physiol Renal Physiol 310 (2016), F547–F559.
48. 48 Dai, D.F., Chen, T., Szeto, H., et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol 58 (2011), 73–82.
49. 49 Liu, S., Soong, Y., Seshan, S.V., et al. Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis. Am J Physiol Renal Physiol 306 (2014), F970–F980.
50. 50 Eirin, A., Williams, B.J., Ebrahimi, B., et al. Mitochondrial targeted peptides attenuate residual myocardial damage after reversal of experimental renovascular hypertension. J Hypertens 32 (2014), 154–165.
51. 51 Eirin, A., Li, Z., Zhang, X., et al. A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis. Hypertension 60 (2012), 1242–1249.
52. 52 Eirin, A., Ebrahimi, B., Zhang, X., et al. Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res 103 (2014), 461–472.
53. 53 Alam, N.M., Mills, W.C., Wong, A.A., et al. A mitochondrial therapeutic reverses visual decline in mouse models of diabetes. Dis Model Mech 8 (2015), 701–710.